Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probenecid effect on sorafenib pharmacokinetics
NL-OMON21261Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sorafenib and probenecid in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary pharmacokinetic endpoint. Started Nov 2017; status: active, not recruiting.
02
Drugs
sorafenibprobenecid
03
Conditions
hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on NL-OMON21261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21261.